ClinicalTrials.gg
CompletedNCT05672862Updated Jan 31, 2023

International Post-PCI FFR Extended Registry

An observational study in Coronary Disease, sponsored by Bon-Kwon Koo. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-01-31.

Sponsored by Bon-Kwon Koo · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,128
Ages
19 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Coronary Disease with a site in Korea, Republic of — 6 open to participants now, 7 under way, none of them phase 3. Coronary Disease · Korea, Republic of.

Enrollment
5th of 20
2,128 · median 1,125
Started
2021
with 3 others
Observational
20 of 49
4 open now
Registered
47th of 49
by date
Lead sponsor
2 of 49
Bon-Kwon Koo

Among the 49 studies in Coronary Disease with a site in Korea, Republic of, this one is the 5th largest by enrollment of the 20 observational ones that give a count, is one of 4 that started in 2021, is one of 20 observational ones, and was the 47th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

6 of the 49 studies in Coronary Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 19 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Coronary Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Percutaneous coronary intervention (PCI) is a standard treatment strategy for coronary artery disease (CAD). With the presence of myocardial ischemia, PCI reduces the risks of death, myocardial infarction (MI), and revascularization compared to medical therapy. However, the risk of future clinical events remains high, and about 10% of patients experienced further cardiovascular events after PCI. Several factors are associated with these poor outcomes. Well-known patient-related risk factors are diabetes mellitus, chronic kidney disease, left ventricular dysfunction, previous MI, and presentation with acute coronary syndrome. Procedure-related factors, such as stent under expansion, malposition, edge dissection, the number of the used stent, and total stent length, are also related to poor prognosis after PCI. Recent studies reported that fractional flow reserve (FFR) after coronary stenting, or post-PCI FFR, was associated with future clinical outcomes after PCI, and low post-PCI FFR value was associated with procedural factors. However, optimal cut-off values of post-PCI FFR ranged widely, from 0.86 to 0.96, and some studies reported the limited prognostic value of post-PCI FFR. This might result from differences in study populations, the definition of outcomes, type of stent used, and distribution of included vessels among previous studies. Previously, the investigators incorporated previous data into the International Post-PCI FFR registry and demonstrated the prognostic value of post-PCI FFR using the machine learning technique. However, the results were based on the two years follow-up of patients after PCI, and the prognostic value of post-PCI FFR in long-term outcomes is still uncertain. Therefore, the investigators planned to extend the International Post-PCI FFR registry to define the long-term prognostic implication of post-PCI FFR.

Read the detailed description

The investigators planned to extend the International Post-PCI FFR registry (NCT04684043) to explore the long-term prognostic value of post-PCI FFR. The International Post-PCI FFR registry (NCT04684043) already included the 2,200 patients who underwent PCI and measured post-PCI FFR between June 2011 and May 2018. As the clinical, angiographic, and physiologic data are already collected in the International Post PCI FFR registry, the investigators will further collect the most recent clinical outcome data until 2021.5 and incorporate them into the International Post-PCI FFR Extended registry. As the current study will evaluate clinical outcomes at 5 years, 2,128 patients who underwent PCI and measured post-PCI FFR between June 2011 and Nov 2016 will be included and studied. The investigators will request further clinical outcome data from 10 hospitals that provided the data for the International Post-PCI FFR registry before.

A standardized form of a spreadsheet, including standardized definitions of variables, was used to collect the individual patient data from the principal investigators of each qualified registry. Patient clinical, angiographic, and physiologic data at the time of index PCI were recorded and already collected at Seoul National University Hospital. As clinical outcome data of 2 years of follow-up after index PCI are already collected in the International Post-PCI FFR registry (NCT04684043), clinical outcome data after 2 years of index PCI will be collected by medical records until 2021.5 of each hospital. All submitted data were double-checked by a central monitoring team in Seoul National University Hospital. All patients' identifying numbers are anonymized as "Subject_No" and the investigators will request the patients' clinical outcome data using these anonymized identifying numbers of the patients. Also, the investigators will share collected data with collaborators, using these numbers.

03

Conditions studied

  • Coronary Disease

Keywords

  • fractional flow reserve
  • percutaneous coronary intervention
  • drug-eluting stent
  • coronary atherosclerosis
04

Who can participate

Ages eligible
19 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who were diagnosed as obstructive coronary artery disease and treated by DES and measured post PCI FFR after PCI.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who underwent PCI and post-PCI FFR measurements after angiographically successful stent implantation (residual stenosis \< 20% by visual estimation)

Exclusion criteria

Exclusion Criteria:

  • Post-PCI TIMI (The Thrombolysis In Myocardial Infarction) flow of \< 3
  • Depressed left ventricular systolic function ( \< 30%)
  • Culprit lesion for the acute coronary syndrome
  • Graft vessel
  • Collateral feeder
  • In-stent stenosis
  • Primary myocardial or valvular heart disease
  • Patients with \< 2 years.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,128 participants (actual)
Patient registry
No

Groups and cohorts

  • Post PCI state

    The study population of this study underwent percutaneous coronary intervention(PCI) with drug-eluting stent (DES) and measured fractional flow reserve after PCI.

    Device: Percutaneous coronary intervention

Interventions

  • DevicePercutaneous coronary intervention

    PCI was performed using drug-eluting stents

06

What researchers measure

Primary outcomes

  1. The cumulative incidence (percent) of target vessel failure

    Target vessel failure is a composite of cardiac death, target vessel myocardial infarction, and target vessel revascularization. The cumulative incidence will be calculated as Kaplan-Mier estimates at 5 years.

    Time frame: 5 years

Secondary outcomes

  1. The cumulative incidence (percent) of cardiac death or myocardial infarction

    This outcome is a composite of cardiac death and target vessel myocardial infarction. The cumulative incidence will be calculated as Kaplan-Mier estimates at 5 years.

    Time frame: 5 years

  2. The cumulative incidence (percent) of target vessel myocardial infarction

    Target vessel myocardial infarction is myocardial infarction that occurred in the target vessel in which post-PCI FFR was measured. The cumulative incidence will be calculated as Kaplan-Mier estimates at 5 years.

    Time frame: 5 years

  3. The cumulative incidence (percent) of target vessel revascularization

    Target vessel revascularization is a revascularization event in the target vessel in which post-PCI FFR was measured. The cumulative incidence will be calculated as Kaplan-Mier estimates at 5 years.

    Time frame: 5 years

Other outcomes

  1. Cut-off value of post-PCI FFR

    Define the best cut-off value for predicting future adverse events. The optimal cut-off value of post-PCI FFR for predicting outcomes was calculated based on maximizing the difference of log-rank statistics.

    Time frame: 5 years

07

Study locations

1 site
  • Bon-Kwon Koo
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10.1093/eurheartj/ehy394. No abstract available. Erratum In: Eur Heart J. 2019 Oct 1;40(37):3096. doi: 10.1093/eurheartj/ehz507. PubMed 30165437 ↗
  • Fearon WF, Nishi T, De Bruyne B, Boothroyd DB, Barbato E, Tonino P, Juni P, Pijls NHJ, Hlatky MA; FAME 2 Trial Investigators. Clinical Outcomes and Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease: Three-Year Follow-Up of the FAME 2 Trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation). Circulation. 2018 Jan 30;137(5):480-487. doi: 10.1161/CIRCULATIONAHA.117.031907. Epub 2017 Nov 2. PubMed 29097450 ↗
  • Montalescot G, Brieger D, Dalby AJ, Park SJ, Mehran R. Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence. J Am Coll Cardiol. 2015 Aug 18;66(7):832-847. doi: 10.1016/j.jacc.2015.05.053. PubMed 26271067 ↗
  • Hwang D, Lee JM, Lee HJ, Kim SH, Nam CW, Hahn JY, Shin ES, Matsuo A, Tanaka N, Matsuo H, Lee SY, Doh JH, Koo BK. Influence of target vessel on prognostic relevance of fractional flow reserve after coronary stenting. EuroIntervention. 2019 Aug 29;15(5):457-464. doi: 10.4244/EIJ-D-18-00913. PubMed 30561367 ↗
  • Li SJ, Ge Z, Kan J, Zhang JJ, Ye F, Kwan TW, Santoso T, Yang S, Sheiban I, Qian XS, Tian NL, Rab TS, Tao L, Chen SL. Cutoff Value and Long-Term Prediction of Clinical Events by FFR Measured Immediately After Implantation of a Drug-Eluting Stent in Patients With Coronary Artery Disease: 1- to 3-Year Results From the DKCRUSH VII Registry Study. JACC Cardiovasc Interv. 2017 May 22;10(10):986-995. doi: 10.1016/j.jcin.2017.02.012. Epub 2017 Apr 26. PubMed 28456699 ↗
  • Rimac G, Fearon WF, De Bruyne B, Ikeno F, Matsuo H, Piroth Z, Costerousse O, Bertrand OF. Clinical value of post-percutaneous coronary intervention fractional flow reserve value: A systematic review and meta-analysis. Am Heart J. 2017 Jan;183:1-9. doi: 10.1016/j.ahj.2016.10.005. Epub 2016 Oct 11. PubMed 27979031 ↗
  • van Zandvoort LJC, Masdjedi K, Witberg K, Ligthart J, Tovar Forero MN, Diletti R, Lemmert ME, Wilschut J, de Jaegere PPT, Boersma E, Zijlstra F, Van Mieghem NM, Daemen J. Explanation of Postprocedural Fractional Flow Reserve Below 0.85. Circ Cardiovasc Interv. 2019 Feb;12(2):e007030. doi: 10.1161/CIRCINTERVENTIONS.118.007030. PubMed 30732469 ↗
  • Piroth Z, Toth GG, Tonino PAL, Barbato E, Aghlmandi S, Curzen N, Rioufol G, Pijls NHJ, Fearon WF, Juni P, De Bruyne B. Prognostic Value of Fractional Flow Reserve Measured Immediately After Drug-Eluting Stent Implantation. Circ Cardiovasc Interv. 2017 Aug;10(8):e005233. doi: 10.1161/CIRCINTERVENTIONS.116.005233. PubMed 28790165 ↗
  • Hwang D, Lee JM, Yang S, Chang M, Zhang J, Choi KH, Kim CH, Nam CW, Shin ES, Kwak JJ, Doh JH, Hoshino M, Hamaya R, Kanaji Y, Murai T, Zhang JJ, Ye F, Li X, Ge Z, Chen SL, Kakuta T, Koo BK. Role of Post-Stent Physiological Assessment in a Risk Prediction Model After Coronary Stent Implantation. JACC Cardiovasc Interv. 2020 Jul 27;13(14):1639-1650. doi: 10.1016/j.jcin.2020.04.041. PubMed 32703590 ↗

Individual participant data

Plan to share: Undecided — This issue has to be discussed with collaborators.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in May 2022, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2021
First posted
Jan 5, 2023
StartActual
Sep 6, 2021
Primary completionActual
May 30, 2022
CompletionActual
Dec 31, 2022
Last update
Jan 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05672862
Lead sponsor
Bon-Kwon Koo
Collaborators
Inje University Ilsan Paik Hospital, Goyang, South Korea, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, Tsuchiura Kyodo General Hospital, Gifu Heart Center, Gifu, Japan, Keimyung University Dongsan Medical Center, Daegu, South Korea, Ulsan University Hospital, Ulsan, South Korea, Samsung Medical Center, Kyoto Second Red Cross Hospital, Kyoto, Japan, Sejong General Hospital
Responsible party
Bon-Kwon Koo (Professor, Seoul National University Hospital) — Sponsor-investigator
First posted
Jan 5, 2023
Start date
Sep 6, 2021
Primary completion
May 30, 2022
Completion
Dec 31, 2022
Last update
Jan 31, 2023

Study contacts

Bon-Kwon Koo, MD
study chair · Seoul National University Hospital, Seoul, South Korea
Joon-Hyung Doh, MD
principal investigator · Inje University Ilsan Paik Hospital, Goyang, South Korea
Shao-Liang Chen, MD
principal investigator · Nanjing First Hospital, Nanjing Medical University, Nanjing, China
Tsunekazu Kakuta, MD
principal investigator · Tsuchiura Kyodo General Hospital
Hitoshi Matsuo, MD
principal investigator · Gifu Heart Center, Gifu, Japan
Chang-Wook Nam, MD
principal investigator · Keimyung University Dongsan Medical Center, Daegu, South Korea
Eun-Seok Shin, MD
principal investigator · Ulsan University Hospital, Ulsan, South Korea
Joo Myung Lee, MD
principal investigator · Samsung Medical Center
Akiko Matsuo, MD
principal investigator · Kyoto Second Red Cross Hospital, Kyoto, Japan
Hyun-Jong Lee, MD
principal investigator · Sejong General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion